EGFR and cancer: Cetuximab is a monoclonal antibody that can specifically bind epidermal growth factor receptor (EGFR) and competitively inhibit EGF and other ligands with the receptor blocking the intracellular signal transduction pathway, thus inhibiting the proliferation of cancer cells, inducing the apoptosis of cancer cells, and reducing MMP and VEGF production.